{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:59:24Z","timestamp":1790801964194,"version":"4.1.0"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,2,28]],"date-time":"2015-02-28T00:00:00Z","timestamp":1425081600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1208\/s12248-015-9738-4","type":"journal-article","created":{"date-parts":[[2015,2,27]],"date-time":"2015-02-27T17:42:37Z","timestamp":1425058957000},"page":"525-534","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Antibody Drug Conjugates: Preclinical Considerations"],"prefix":"10.1208","volume":"17","author":[{"given":"Gadi G.","family":"Bornstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,28]]},"reference":[{"key":"9738_CR1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/202255a0","volume":"202","author":"S Decarvalho","year":"1964","unstructured":"Decarvalho S, Rand HJ, Lewis A. Coupling of cyclic chemotherapeutic compounds to immune gamma-globulins. Nature. 1964;202:255\u20138.","journal-title":"Nature"},{"issue":"5","key":"9738_CR2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrd4009","volume":"12","author":"A Mullard","year":"2013","unstructured":"Mullard A. Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov. 2013;12(5):329\u201332.","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"9738_CR3","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1158\/1535-7163.MCT-09-0369","volume":"8","author":"B Zheng","year":"2009","unstructured":"Zheng B, Fuji RN, Elkins K, et al. In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates. Mol Cancer Ther. 2009;8(10):2937\u201346.","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"9738_CR4","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/mt.2012.103","volume":"20","author":"JH Graversen","year":"2012","unstructured":"Graversen JH, Svendsen P, Dagnaes-Hansen F, et al. Targeting the hemoglobin scavenger receptor CD163 in macrophages highly increases the anti-inflammatory potency of dexamethasone. Mol Ther. 2012;20(8):1550\u20138.","journal-title":"Mol Ther"},{"issue":"3","key":"9738_CR5","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4161\/mabs.1.3.8515","volume":"1","author":"HP Gerber","year":"2009","unstructured":"Gerber HP, Senter PD, Grewal IS. Antibody drug-conjugates targeting the tumor vasculature: current and future developments. MAbs. 2009;1(3):247\u201353.","journal-title":"MAbs"},{"key":"9738_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-62703-541-5_1","volume":"1045","author":"I Sassoon","year":"2013","unstructured":"Sassoon I, Blanc V. Antibody-drug conjugate (ADC) clinical pipeline: a review. Methods Mol Biol. 2013;1045:1\u201327.","journal-title":"Methods Mol Biol"},{"key":"9738_CR7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-1-62703-541-5_2","volume":"1045","author":"NH Bander","year":"2013","unstructured":"Bander NH. Antibody-drug conjugate target selection: critical factors. Methods Mol Biol. 2013;1045:29\u201340.","journal-title":"Methods Mol Biol"},{"issue":"8","key":"9738_CR8","first-page":"LB","volume":"73","author":"J Baselga","year":"2013","unstructured":"Baselga J, Verma S, Ro J, et al. Relationship between tumor biomarkers and efficacy in EMILIA, a phase III study of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer. Cancer Res. 2013;73(8):LB\u201363.","journal-title":"Cancer Res"},{"issue":"7","key":"9738_CR9","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.drudis.2013.11.004","volume":"19","author":"HL Perez","year":"2014","unstructured":"Perez HL, Cardarelli PM, Deshpande S, et al. Antibody-drug conjugates: current status and future directions. Drug Discov Today. 2014;19(7):869\u201381.","journal-title":"Drug Discov Today"},{"key":"9738_CR10","first-page":"953","volume":"5","author":"MF Press","year":"1990","unstructured":"Press MF et al. Expression of the HER-2\/neu proto-oncogene in normal human adult and fetal tissues. Oncogene. 1990;5:953\u201362.","journal-title":"Oncogene"},{"issue":"Suppl 1","key":"9738_CR11","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S0145-2126(06)80004-4","volume":"30","author":"P Solal-Celligny","year":"2006","unstructured":"Solal-Celligny P. Safety of rituximab maintenance therapy in follicular lymphomas. Leuk Res. 2006;30 Suppl 1:S16\u201321.","journal-title":"Leuk Res"},{"key":"9738_CR12","first-page":"3736","volume":"62","author":"AF Wahl","year":"2002","unstructured":"Wahl AF, Klussman K, Thompson JD, et al. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin\u2019s disease. Cancer Res. 2002;62:3736\u201342.","journal-title":"Cancer Res"},{"key":"9738_CR13","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1182\/blood.V96.12.3681","volume":"96","author":"H Stein","year":"2000","unstructured":"Stein H, Foss HD, Durkop H, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96:3681\u201395.","journal-title":"Blood"},{"key":"9738_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V85.1.1.bloodjournal8511","volume":"85","author":"B Falini","year":"1995","unstructured":"Falini B, Pileri S, Pizzolo G, et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood. 1995;85:1\u201314.","journal-title":"Blood"},{"key":"9738_CR15","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1021\/ar700108g","volume":"41","author":"RVJ Chari","year":"2008","unstructured":"Chari RVJ. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res. 2008;41:98\u2013107.","journal-title":"Acc Chem Res"},{"issue":"7","key":"9738_CR16","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nbt832","volume":"21","author":"SO Doronina","year":"2003","unstructured":"Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21(7):778\u201384.","journal-title":"Nat Biotechnol"},{"issue":"8","key":"9738_CR17","doi-asserted-by":"crossref","first-page":"982","DOI":"10.2174\/156800909790192365","volume":"9","author":"BA Teicher","year":"2009","unstructured":"Teicher BA. Antibody-drug conjugate targets. Curr Cancer Drug Targets. 2009;9(8):982\u20131004.","journal-title":"Curr Cancer Drug Targets"},{"issue":"4","key":"9738_CR18","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1677\/erc.1.00766","volume":"11","author":"P Carter","year":"2004","unstructured":"Carter P, Smith L, Ryan M. Identification and validation of cell surface antigens for antibody targeting in oncology. Endocrinol Relat Cancer. 2004;11(4):659\u201387.","journal-title":"Endocrinol Relat Cancer"},{"issue":"1","key":"9738_CR19","doi-asserted-by":"crossref","first-page":"8","DOI":"10.13172\/2053-3918-1-1-753","volume":"1","author":"MA Firer","year":"2013","unstructured":"Firer MA. Antibody-drug conjugates in cancer therapy\u2014filling in the potholes that lie ahead. OA Cancer. 2013;1(1):8.","journal-title":"OA Cancer"},{"issue":"3","key":"9738_CR20","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1124\/jpet.109.155549","volume":"330","author":"SC Alley","year":"2009","unstructured":"Alley SC, Zhang X, Okeley NM, et al. The pharmacologic basis for antibody-auristatin conjugate activity. J Pharmacol Exp Ther. 2009;330(3):932\u20138.","journal-title":"J Pharmacol Exp Ther"},{"key":"9738_CR21","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.addr.2008.04.012","volume":"60","author":"GM Thurber","year":"2008","unstructured":"Thurber GM, Schmidt MM, Wittrup KD, et al. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev. 2008;60:1421\u201334.","journal-title":"Adv Drug Deliv Rev"},{"key":"9738_CR22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1146\/annurev-med-050311-201823","volume":"64","author":"EL Sievers","year":"2013","unstructured":"Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med. 2013;64:15\u201329.","journal-title":"Annu Rev Med"},{"key":"9738_CR23","doi-asserted-by":"crossref","first-page":"7842","DOI":"10.1158\/1078-0432.CCR-04-1028","volume":"10","author":"CL Law","year":"2004","unstructured":"Law CL, Cerveny CG, Gordon KA, et al. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates. Clin Cancer Res. 2004;10:7842\u201351.","journal-title":"Clin Cancer Res"},{"key":"9738_CR24","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1158\/1535-7163.MCT-06-0026","volume":"5","author":"LM Smith","year":"2006","unstructured":"Smith LM, Nesterova A, Alley SC, Torgov MY, Carter PJ. Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin\/p97. Mol Cancer Ther. 2006;5:1474\u201382.","journal-title":"Mol Cancer Ther"},{"key":"9738_CR25","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1182\/blood-2012-12-468363","volume":"121","author":"M Yoshikawa","year":"2013","unstructured":"Yoshikawa M, Mukai Y, Okada Y, et al. Robo4 is an effective tumor endothelial marker for antibody-drug conjugates based on the rapid isolation of the anti-Robo4 cell-internalizing antibody. Blood. 2013;121:2804\u201313.","journal-title":"Blood"},{"issue":"7","key":"9738_CR26","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1158\/1535-7163.MCT-08-0067","volume":"7","author":"ME Ackerman","year":"2008","unstructured":"Ackerman ME, Pawlowski D, Wittrup KD, et al. Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids. Mol Cancer Ther. 2008;7(7):2233\u201340.","journal-title":"Mol Cancer Ther"},{"key":"9738_CR27","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nri1837","volume":"6","author":"PJ Carter","year":"2006","unstructured":"Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol. 2006;6:343\u201357.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"9738_CR28","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jconrel.2013.07.011","volume":"172","author":"SC Owen","year":"2013","unstructured":"Owen SC, Patel N, Logie J, et al. Targeting HER2+ breast cancer cells: lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles. J Control Release. 2013;172(2):395\u2013404.","journal-title":"J Control Release"},{"issue":"6","key":"9738_CR29","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1158\/0008-5472.CAN-10-2277","volume":"71","author":"SI Rudnick","year":"2011","unstructured":"Rudnick SI, Lou J, Shaller CC, et al. Influence of affinity and antigen internalization on the uptake and penetration of anti-HER2 antibodies in solid tumors. Cancer Res. 2011;71(6):2250\u20139.","journal-title":"Cancer Res"},{"key":"9738_CR30","first-page":"113","volume":"81","author":"JA Flygare","year":"2013","unstructured":"Flygare JA, Pillow TH, Aristoff P. Antibody-drug conjugates for the treatment of cancer. Chem Biol Des. 2013;81:113\u201321.","journal-title":"Chem Biol Des"},{"issue":"21","key":"9738_CR31","doi-asserted-by":"crossref","first-page":"7995","DOI":"10.1158\/0008-5472.CAN-04-1722","volume":"64","author":"MD Henry","year":"2004","unstructured":"Henry MD, Wen S, Silva MD, et al. A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res. 2004;64(21):7995\u20138001.","journal-title":"Cancer Res"},{"key":"9738_CR32","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1182\/blood.V110.11.1850.1850","volume":"110","author":"O Legrand","year":"2007","unstructured":"Legrand O. An open label dose escalation study of AVE9633 administered as a single agent by intravenous (IV) infusion weekly for 2 weeks in 4-week cycle to patients with relapsed or refractory CD33-positive acute myeloid leukemia (AML). Blood. 2007;110:1850.","journal-title":"Blood"},{"issue":"6","key":"9738_CR33","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1158\/0008-5472.CAN-08-2250","volume":"69","author":"AG Polson","year":"2009","unstructured":"Polson AG, Calemine-Fenaux J, Chan P, et al. Antibody-drug conjugates for the treatment of non-Hodgkin\u2019s lymphoma: target and linker-drug selection. Cancer Res. 2009;69(6):2358\u201364.","journal-title":"Cancer Res"},{"issue":"12","key":"9738_CR34","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1182\/blood-2004-03-0963","volume":"104","author":"P Tassone","year":"2004","unstructured":"Tassone P, Goldmacher VS, Neri P, et al. Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood. 2004;104(12):3688\u201396.","journal-title":"Blood"},{"issue":"13","key":"9738_CR35","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1158\/0008-5472.CAN-04-0142","volume":"64","author":"P Tassone","year":"2004","unstructured":"Tassone P, Gozzini A, Goldmacher VS, et al. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2\u2019-deacetyl-N2\u2019-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Res. 2004;64(13):4629\u201336.","journal-title":"Cancer Res"},{"issue":"22","key":"9738_CR36","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","volume":"68","author":"GD Lewis Phillips","year":"2008","unstructured":"Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68(22):9280\u201390.","journal-title":"Cancer Res"},{"key":"9738_CR37","doi-asserted-by":"crossref","first-page":"6428","DOI":"10.1158\/1078-0432.CCR-11-0488","volume":"17","author":"J Katz","year":"2011","unstructured":"Katz J, Janik JE, Younes A. Brentuximab vedotin (SGN-35). Clin Cancer Res. 2011;17:6428\u201336.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"9738_CR38","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.canlet.2007.04.010","volume":"255","author":"YV Kovtun","year":"2007","unstructured":"Kovtun YV, Goldmacher VS. Cell killing by antibody-drug conjugates. Cancer Lett. 2007;255(2):232\u201340.","journal-title":"Cancer Lett"},{"issue":"1","key":"9738_CR39","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1021\/bc010021y","volume":"13","author":"PR Hamann","year":"2002","unstructured":"Hamann PR, Hinman LM, Hollander I, et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem. 2002;13(1):47\u201358.","journal-title":"Bioconjug Chem"},{"issue":"1","key":"9738_CR40","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1021\/bc0100206","volume":"13","author":"PR Hamann","year":"2002","unstructured":"Hamann PR, Hinman LM, Beyer CF, et al. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug Chem. 2002;13(1):40\u20136.","journal-title":"Bioconjug Chem"},{"key":"9738_CR41","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/nrd2137","volume":"8","author":"BB Zhou","year":"2009","unstructured":"Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov. 2009;8:806\u201323.","journal-title":"Nat Rev Drug Discov"},{"key":"9738_CR42","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","volume":"53","author":"MM Gottesman","year":"2002","unstructured":"Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002;53:615\u201327.","journal-title":"Annu Rev Med"},{"issue":"6","key":"9738_CR43","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/cyto.990050612","volume":"5","author":"OS Frankfurt","year":"1984","unstructured":"Frankfurt OS, Greco WR, Slocum HK, et al. Proliferative characteristics of primary and metastatic human solid tumors by DNA flow cytometry. Cytometry. 1984;5(6):629\u201335.","journal-title":"Cytometry"},{"issue":"4","key":"9738_CR44","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/(SICI)1096-9098(199708)65:4<284::AID-JSO11>3.0.CO;2-2","volume":"65","author":"S Friberg","year":"1997","unstructured":"Friberg S, Mattson SJ. On the growth rates of human malignant tumors: implications for medical decision making. Surg Oncol. 1997;65(4):284\u201397.","journal-title":"Surg Oncol"},{"key":"9738_CR45","first-page":"1660","volume":"56","author":"L Hlatky","year":"1996","unstructured":"Hlatky L, Olesiak M, Hahnfeldt P. Measurement of potential doubling time for human tumor xenografts using the cytokinesis-block method. Cancer Res. 1996;56:1660\u20133.","journal-title":"Cancer Res"},{"issue":"5","key":"9738_CR46","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1182\/blood-2003-07-2466","volume":"103","author":"JF DiJoseph","year":"2004","unstructured":"DiJoseph JF, Armellino DC, Boghaert ER, et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood. 2004;103(5):1807\u201314.","journal-title":"Blood"},{"issue":"1","key":"9738_CR47","first-page":"221","volume":"32","author":"ER Boghaert","year":"2008","unstructured":"Boghaert ER, Sridharan L, Khandke KM, et al. The oncofetal protein, 5T4, is a suitable target for antibody-guided anti-cancer chemotherapy with calicheamicin. Int J Oncol. 2008;32(1):221\u201334.","journal-title":"Int J Oncol"},{"issue":"6","key":"9738_CR48","first-page":"1490","volume":"7","author":"PF Bross","year":"2001","unstructured":"Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7(6):1490\u20136.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"9738_CR49","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1470-2045(11)70386-2","volume":"13","author":"H Kantarjian","year":"2012","unstructured":"Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012;13(4):403\u201311.","journal-title":"Lancet Oncol"},{"issue":"3","key":"9738_CR50","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.cbpa.2009.03.023","volume":"13","author":"PD Senter","year":"2009","unstructured":"Senter PD. Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol. 2009;13(3):235\u201344.","journal-title":"Curr Opin Chem Biol"},{"issue":"3","key":"9738_CR51","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1021\/bc00009a001","volume":"2","author":"T Kaneko","year":"1991","unstructured":"Kaneko T, Willner D, Monkovic I, et al. New hydrazone derivatives of adriamycin and their immunoconjugates\u2014a correlation between acid stability and cytotoxicity. Bioconjug Chem. 1991;2(3):133\u201341.","journal-title":"Bioconjug Chem"},{"issue":"1","key":"9738_CR52","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1021\/bc9002019","volume":"21","author":"L Ducry","year":"2010","unstructured":"Ducry L, Stump B. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem. 2010;21(1):5\u201313.","journal-title":"Bioconjug Chem"},{"issue":"6","key":"9738_CR53","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1021\/jo016187+","volume":"67","author":"BE Toki","year":"2002","unstructured":"Toki BE, Cerveny CG, Wahl AF, Senter PD. Protease-mediated fragmentation of p-amidobenzyl ethers: a new strategy for the activation of anticancer prodrugs. J Org Chem. 2002;67(6):1866\u201372.","journal-title":"J Org Chem"},{"issue":"11","key":"9738_CR54","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/S0960-894X(02)00194-4","volume":"12","author":"GM Dubowchik","year":"2002","unstructured":"Dubowchik GM, Radia S, Mastalerz H, et al. Doxorubicin immunoconjugates containing bivalent, lysosomally-cleavable dipeptide linkages. Bioorg Med Chem Lett. 2002;12(11):1529\u201332.","journal-title":"Bioorg Med Chem Lett"},{"issue":"4","key":"9738_CR55","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.coph.2005.04.008","volume":"5","author":"P Polakis","year":"2005","unstructured":"Polakis P. Arming antibodies for cancer therapy. Curr Opin Pharmacol. 2005;5(4):382\u20137.","journal-title":"Curr Opin Pharmacol"},{"issue":"9","key":"9738_CR56","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/nbt1141","volume":"23","author":"AM Wu","year":"2005","unstructured":"Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol. 2005;23(9):1137\u201346.","journal-title":"Nat Biotechnol"},{"key":"9738_CR57","doi-asserted-by":"crossref","unstructured":"KovtunYV, Audette CA, Ye Y, et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 66(6):3214\u201321.","DOI":"10.1158\/0008-5472.CAN-05-3973"},{"key":"9738_CR58","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1021\/bc900315y","volume":"21","author":"HK Erickson","year":"2010","unstructured":"Erickson HK, Widdison WC, Mayo MF, et al. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem. 2010;21:84\u201392.","journal-title":"Bioconjug Chem"},{"key":"9738_CR59","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1158\/1078-0432.CCR-09-2069","volume":"16","author":"NM Okeley","year":"2010","unstructured":"Okeley NM, Miyamaoto JB, Zhang X, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res. 2010;16:888\u201397.","journal-title":"Clin Cancer Res"},{"key":"9738_CR60","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/cbdd.12085","volume":"81","author":"JA Flygare","year":"2013","unstructured":"Flygare JA, Pillow TH, Aristoff P. Antibody-drug conjugates for the treatment of cancer. Chem Biol Drug Des. 2013;81:113\u201321.","journal-title":"Chem Biol Drug Des"},{"key":"9738_CR61","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1158\/1078-0432.843.11.2","volume":"11","author":"RJ Sanderson","year":"2005","unstructured":"Sanderson RJ, Hering MA, James SF, et al. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res. 2005;11:843\u201352.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"9738_CR62","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/protein\/gzl013","volume":"19","author":"CF McDonagh","year":"2006","unstructured":"McDonagh CF, Turcott E, Westendorf L, et al. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng Des Sel. 2006;19(7):299\u2013307.","journal-title":"Protein Eng Des Sel"},{"issue":"20","key":"9738_CR63","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","volume":"10","author":"KJ Hamblett","year":"2004","unstructured":"Hamblett KJ, Senter PD, Chace DF, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10(20):7063\u201370.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"9738_CR64","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.chembiol.2013.01.010","volume":"20","author":"P Strop","year":"2013","unstructured":"Strop P, Liu SH, Dorywalska M, et al. Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem Biol. 2013;20(2):161\u20137.","journal-title":"Chem Biol"},{"key":"9738_CR65","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/nbt1137","volume":"23","author":"GP Adams","year":"2005","unstructured":"Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol. 2005;23:1147\u201357.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"9738_CR66","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/BF01518520","volume":"37","author":"GD Lewis","year":"1993","unstructured":"Lewis GD, Figari I, Fendly B, et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother. 1993;37(4):255\u201363.","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"9738_CR67","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10549-010-1090-x","volume":"128","author":"TT Junttila","year":"2011","unstructured":"Junttila TT, Li G, Parsons K, et al. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat. 2011;128(2):347\u201356.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"9738_CR68","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1182\/blood.V98.4.988","volume":"98","author":"ML Linenberger","year":"2001","unstructured":"Linenberger ML, Hong T, Flowers D, et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood. 2001;98(4):988\u201394.","journal-title":"Blood"},{"issue":"2","key":"9738_CR69","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/sj.leu.2403598","volume":"19","author":"ML Linenberger","year":"2005","unstructured":"Linenberger ML. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia. 2005;19(2):176\u201382.","journal-title":"Leukemia"},{"issue":"10","key":"9738_CR70","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2006-09-047399","volume":"109","author":"RB Walter","year":"2007","unstructured":"Walter RB, Gooley TA, van der Velden VH, et al. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood. 2007;109(10):4168\u201370.","journal-title":"Blood"},{"key":"9738_CR71","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/1471-2407-9-199","volume":"9","author":"R Tang","year":"2009","unstructured":"Tang R, Cohen S, Perrot JY, et al. P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients. BMC Cancer. 2009;9:199.","journal-title":"BMC Cancer"},{"issue":"6","key":"9738_CR72","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1158\/0008-5472.CAN-09-3546","volume":"70","author":"YV Kovtun","year":"2010","unstructured":"Kovtun YV, Audette CA, Mayo MF, et al. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res. 2010;70(6):2528\u201337.","journal-title":"Cancer Res"},{"issue":"6","key":"9738_CR73","first-page":"3183","volume":"46","author":"AA Espenetos","year":"1986","unstructured":"Espenetos AA, Snook D, Durbin H, et al. Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms. Cancer Res. 1986;46(6):3183\u201391.","journal-title":"Cancer Res"},{"issue":"1","key":"9738_CR74","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/scientificamerican0794-58","volume":"271","author":"RK Jain","year":"1994","unstructured":"Jain RK. Barriers to drug delivery in solid tumors. Sci Am. 1994;271(1):58\u201365.","journal-title":"Sci Am"},{"issue":"1","key":"9738_CR75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10739689709148314","volume":"4","author":"JRK The","year":"1997","unstructured":"The JRK, Eugene M. Landis Award Lecture 1996. Delivery of molecular and cellular medicine to solid tumors. Microcirculation. 1997;4(1):1\u201323.","journal-title":"Microcirculation"},{"issue":"4","key":"9738_CR76","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/nrc778","volume":"2","author":"RK Jain","year":"2002","unstructured":"Jain RK, Munn LL, Fukumura D. Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer. 2002;2(4):266\u201376.","journal-title":"Nat Rev Cancer"},{"issue":"16","key":"9738_CR77","first-page":"4324","volume":"60","author":"AJ Leu","year":"2000","unstructured":"Leu AJ, Berk DA, Lymboussaki A, Alitalo K, Jain RK. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res. 2000;60(16):4324\u20137.","journal-title":"Cancer Res"},{"issue":"10","key":"9738_CR78","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/nrc1456","volume":"4","author":"CH Heldin","year":"2004","unstructured":"Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure\u2014an obstacle in cancer therapy. Nat Rev Cancer. 2004;4(10):806\u201313.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"9738_CR79","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1002\/(SICI)1097-0142(19980615)82:12<2418::AID-CNCR16>3.0.CO;2-S","volume":"82","author":"MF Milosevic","year":"1998","unstructured":"Milosevic MF, Fyles AW, Wong R, Pintilie M, Kavanagh MC, Levin W, et al. Interstitial fluid pressure in cervical carcinoma: within tumor heterogeneity, and relation to oxygen tension. Cancer. 1998;82(12):2418\u201326.","journal-title":"Cancer"},{"issue":"12","key":"9738_CR80","first-page":"3039","volume":"47","author":"RK Jain","year":"1987","unstructured":"Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res. 1987;47(12):3039\u201351.","journal-title":"Cancer Res"},{"issue":"11","key":"9738_CR81","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/nrc1478","volume":"4","author":"RA Gatenby","year":"2004","unstructured":"Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4(11):891\u20139.","journal-title":"Nat Rev Cancer"},{"issue":"16","key":"9738_CR82","first-page":"4373","volume":"49","author":"IF Tannock","year":"1989","unstructured":"Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 1989;49(16):4373\u201384.","journal-title":"Cancer Res"},{"key":"9738_CR83","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1158\/1535-7163.MCT-08-0388","volume":"7","author":"KM Kim","year":"2008","unstructured":"Kim KM, McDonagh CF, Westendorf L, et al. Anti-CD30 diabody\u2014drug conjugates with potent antitumor activity. Mol Cancer Ther. 2008;7:2486\u201397.","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"9738_CR84","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1054\/bjoc.2001.1797","volume":"84","author":"DR Newell","year":"2001","unstructured":"Newell DR. Flasks, fibres and flanks\u2014pre-clinical tumour models for predicting clinical antitumor activity. Br J Cancer. 2001;84(10):1289\u201390.","journal-title":"Br J Cancer"},{"issue":"10","key":"9738_CR85","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1054\/bjoc.2001.1796","volume":"84","author":"JI Johnson","year":"2001","unstructured":"Johnson JI, Decker S, Zaharevitz D, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer. 2001;84(10):1424\u201331.","journal-title":"Br J Cancer"},{"key":"9738_CR86","doi-asserted-by":"crossref","unstructured":"Plowman J, Dykes DJ, Hollingshead M, et al. Anticancer drug development guide. Cancer Drug Discov Dev. 1997:101-125.","DOI":"10.1007\/978-1-4615-8152-9_6"},{"key":"9738_CR87","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1023\/A:1006326203858","volume":"17","author":"RM Hoffman","year":"1999","unstructured":"Hoffman RM. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Investig New Drugs. 1999;17:343\u201359.","journal-title":"Investig New Drugs"},{"key":"9738_CR88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bjc.1983.1","volume":"47","author":"GG Steel","year":"1983","unstructured":"Steel GG et al. The response to chemotherapy of a variety of human tumour xenografts. Br J Cancer. 1983;47:1\u201313.","journal-title":"Br J Cancer"},{"key":"9738_CR89","doi-asserted-by":"crossref","first-page":"8624","DOI":"10.1073\/pnas.1633646100","volume":"100","author":"JD Hood","year":"2003","unstructured":"Hood JD, Cheresh DA. Building a better trap. Proc Natl Acad Sci U S A. 2003;100:8624\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9738_CR90","doi-asserted-by":"crossref","first-page":"6456","DOI":"10.1158\/1078-0432.CCR-08-0138","volume":"14","author":"I Fichtner","year":"2008","unstructured":"Fichtner I, Rolff J, Soong R, et al. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res. 2008;14:6456\u201368.","journal-title":"Clin Cancer Res"},{"key":"9738_CR91","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1182\/blood-2005-06-2298","volume":"106","author":"KD Lute","year":"2005","unstructured":"Lute KD, May Jr KF, Lu P, et al. Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies. Blood. 2005;106:3127\u201333.","journal-title":"Blood"},{"issue":"5\u20136","key":"9738_CR92","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.drudis.2008.12.008","volume":"14","author":"MA Tabrizi","year":"2009","unstructured":"Tabrizi MA, Bornstein GG, Klakamp SL, et al. Translational strategies for development of monoclonal antibodies from discovery to the clinic. Drug Discov Today. 2009;14(5\u20136):298\u2013305.","journal-title":"Drug Discov Today"},{"key":"9738_CR93","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/0145-2126(84)90001-8","volume":"8","author":"JD Griffin","year":"1984","unstructured":"Griffin JD, Linch D, Sabbath K, et al. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res. 1984;8:521\u201334.","journal-title":"Leuk Res"},{"key":"9738_CR94","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1021\/bc010021y","volume":"13","author":"PR Hamann","year":"2002","unstructured":"Hamann PR, Hinman LM, Hollander I, et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem. 2002;13:47\u201358.","journal-title":"Bioconjug Chem"},{"key":"9738_CR95","first-page":"1490","volume":"7","author":"PF Bross","year":"2001","unstructured":"Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7:1490\u20136.","journal-title":"Clin Cancer Res"},{"key":"9738_CR96","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3109\/10428194.2012.656102","volume":"53","author":"T Matusmoto","year":"2012","unstructured":"Matusmoto T, Jimi S, Hara S, et al. Importance of inducible multidrug resistance1 expression in HL-60 cells resistant to gemtuzumab ozogamicin. Leuk Lymphoma. 2012;53:1399\u2013405.","journal-title":"Leuk Lymphoma"},{"key":"9738_CR97","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1182\/blood.V97.10.3197","volume":"97","author":"VH Velden van Der","year":"2001","unstructured":"van Der Velden VH, te Marvelde JG, Hoogeveen PG, et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood. 2001;97:3197\u2013204.","journal-title":"Blood"},{"key":"9738_CR98","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.coph.2005.04.008","volume":"5","author":"P Polakis","year":"2005","unstructured":"Polakis P. Arming antibodies for cancer therapy. Curr Opin Pharmacol. 2005;5:382\u20137.","journal-title":"Curr Opin Pharmacol"},{"key":"9738_CR99","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.leukres.2006.07.005","volume":"31","author":"JM McKoy","year":"2007","unstructured":"McKoy JM, Angelotta C, Bennett CL, et al. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res. 2007;31:599\u2013604.","journal-title":"Leuk Res"},{"key":"9738_CR100","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/cncr.21326","volume":"104","author":"RA Larson","year":"2005","unstructured":"Larson RA, Sievers EL, Stadtmaeur EA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005;104:1442\u201352.","journal-title":"Cancer"},{"key":"9738_CR101","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1182\/blood-2007-09-114165","volume":"112","author":"MB Maniecki","year":"2008","unstructured":"Maniecki MB, Hasle H, Fris-Hansen L, et al. Impaired CD163-mediated hemoglobin-scavenging and severe toxic symptoms in patients treated with gemtuzumab ozogamicin. Blood. 2008;112:1510\u20134.","journal-title":"Blood"},{"key":"9738_CR102","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1016\/j.leukres.2011.01.025","volume":"35","author":"MB Maniecki","year":"2011","unstructured":"Maniecki MB, Hasle H, Bendix K, et al. Is hepatotoxicity in patients treated with gentuzumab ozogamicin due to specific targeting of hepatocytes? Leuk Res. 2011;35:e84\u20136.","journal-title":"Leuk Res"},{"key":"9738_CR103","first-page":"57","volume":"4","author":"F Lo Coco","year":"2006","unstructured":"Lo Coco F, Ammatuna E, Noguera N. Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin. Clin Adv Hematol Oncol. 2006;4:57\u201362.","journal-title":"Clin Adv Hematol Oncol"},{"key":"9738_CR104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1034\/j.1600-0609.2003.00084.x","volume":"71","author":"A Candoni","year":"2003","unstructured":"Candoni A, Damiani D, Michelutti A, et al. Clinical characteristics, prognostic factors and multidrug resistance related protein expression in 36 adult patients with acute promyelocytic leukemia. Eur J Haematol. 2003;71:1\u20138.","journal-title":"Eur J Haematol"},{"key":"9738_CR105","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","volume":"29","author":"AK Burnett","year":"2011","unstructured":"Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29:369\u201377.","journal-title":"J Clin Oncol"},{"key":"9738_CR106","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/cncr.25554","volume":"117","author":"T Prebet","year":"2011","unstructured":"Prebet T, Etienne A, Devillier R, et al. Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabrine: results of a retrospective comparative study. Cancer. 2011;117:974\u201381.","journal-title":"Cancer"},{"key":"9738_CR107","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1517\/14712590903348135","volume":"9","author":"G Manoukian","year":"2009","unstructured":"Manoukian G, Hagemeister F. Denileukin diftitox: a novel immunotoxin. Expert Opin Biol Ther. 2009;9:1445\u201351.","journal-title":"Expert Opin Biol Ther"},{"key":"9738_CR108","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1067\/mjd.2001.117852","volume":"45","author":"A Martin","year":"2001","unstructured":"Martin A, Gutierrez E, Muglia J, et al. A multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB389IL-2) in patients with severe psoriasis. J Am Acad Dermatol. 2001;45:871\u20138.","journal-title":"J Am Acad Dermatol"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-015-9738-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12248-015-9738-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-015-9738-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T21:04:45Z","timestamp":1691442285000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12248-015-9738-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,28]]},"references-count":108,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["9738"],"URL":"https:\/\/doi.org\/10.1208\/s12248-015-9738-4","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,28]]}}}